US Venture Partners, a venture capital investment firm, led a $53m Series E round in MicroTransponder, a medical device company, with participation from GPG Ventures, Exceller Hunt Ventures, Osage University Partners, Action Potential Venture Capital and The Vertical Group. "I'm enthusiastic about the MicroTransponder team and the success they have had in building the clinical foundation for Vivistim. The quality of the clinical evidence can lead the therapy to become the standard of care and significantly improve outcomes for stroke survivors," Casey Tansey, US Venture Partners General Partner.